急性白血病患者化疗前后IL-2及IL-6水平的变化及临床意义

The changes and clinical significance of levels of IL-2 and IL-6 in pre and post chemotherapy of acute leukemia patients

目的研究急性白血病患者化疗前后免疫功能的变化,探讨IL-2L-6的水平与患者预后的关系,并为临床治疗提供理论依据。方法应用放射免疫分析法对84例急性白血病患者进行化疗前后血清IL-2、IL-6含量检测,并与30例正常健康人作对照。结果急性白血病初治组及短期CR组IL-2水平分别为(18.76±9.43)ng/L,(29.48±6.39)ng/L明显低于长期CR组(46.73±8.26)ng/L及正常对照组(53.61±8.92)ng/L;初治组及短期CR组IL-6水平分别为(126.38±15.62)ng/L,(82.34±10.18)ng/L明显高于长期CR组(30.35±7.65)ng/L及正常对照组(23.52±6.25)ng/L。初治组IL-2和IL-6水平与长期CR组及正常对照组比较,差异有显著性,P<0.05。结论初治及短期CR急性白血病患者体内以Th2型细胞因子占优势,造成免疫抑制状态,与IL-2、IL-6水平有关,白血病易于复发。随着CR时间的延长免疫状态逐渐恢复。IL-2、IL-6的水平可作为临床上评估患者免疫状态和预后的指标。

Objective To study the change of immune function of serum IL-2 and ID6 of acute Leukemia patients in pre and post, and provide the theoretical foundation for effective immunotherapy. Methods Levels of serum IL-2 and IL-6 were detected by MTr biochemical methods in 84 patients with acute leukemia and 30 normal controls. Results Compared with long stage CR patients （46.73 ± 8.26 ng/L,30.35± 7!65 ng/L） and healthy controls（53.61 ± 8.92 ng/L,23.52± 6.25 ng/L）,the IL-2 levels decreased significantly and the IL-6 levels increased significantly in first visits（18.76 ± 9.43 ng/L,126.38 ± 15.62 ng/L） and short stage CR patients（29.48 ± 6.39 ng/L,82.34 ± 10.18 ng/L）. Compared with long stage CaR patients and healthy controls,there were significant difference in first visit patients, P 〈 0.05. Conclusion Th2 type cytokines were dominant in the first visit and short stage CR acute leukemia patients and contributed to the immunosuppressive state,leukemia was easy to recurring and related to the levels of IL-2 and IL-6. Along with time extent in CR stage,the immunological function recoved gradually. Therefore we could estimate immune function of the acute leukemia patients and prognosis by assaying the levels of IL-2 and IL-6.